Journal Scans
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Trastuzumab Plus Anastrozole in Postmenopausal HER2+/HR+ Metastatic Breast Cancer
B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, S Tjulandin, M Jahn, M Lehle, A Feyereislova, C Révil, A Jones
20090828
2009 Sept 28
J Clin Oncol
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
J Clin Oncol. 2009 Sept 28; Epub ahead of print, B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, S Tjulandin, M Jahn, M Lehle, A Feyereislova, C Révil, A Jones
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Trastuzumab is an effective treatment in women with human epidermal growth factor receptor 2 (HER2)−positive metastatic breast cancer, regardless of hormone receptor (HR) status. HR status is used to select patients with breast cancer in whom hormone therapy is appropriate. However, among women with tumors that are both estrogen receptor (ER) and progesterone receptor (PR) positive (ie, HR copositive), those whose tumors are also HER2 positive may receive less benefit from hormonal therapy than those...
